Radiopharm Theranostics Management
Management criteria checks 2/4
Radiopharm Theranostics' CEO is Riccardo Canevari, appointed in Sep 2021, has a tenure of 3.25 years. total yearly compensation is A$2.65M, comprised of 31.8% salary and 68.2% bonuses, including company stock and options. directly owns 0.97% of the company’s shares, worth A$508.32K. The average tenure of the management team and the board of directors is 3.2 years and 2.8 years respectively.
Key information
Riccardo Canevari
Chief executive officer
AU$2.7m
Total compensation
| CEO salary percentage | 31.8% |
| CEO tenure | 3.3yrs |
| CEO ownership | 1.0% |
| Management average tenure | 3.2yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$3m | AU$844k | -AU$48m |
| Mar 31 2024 | n/a | n/a | -AU$47m |
| Dec 31 2023 | n/a | n/a | -AU$47m |
| Sep 30 2023 | n/a | n/a | -AU$41m |
| Jun 30 2023 | AU$3m | AU$825k | -AU$35m |
| Mar 31 2023 | n/a | n/a | -AU$30m |
| Dec 31 2022 | n/a | n/a | -AU$26m |
| Sep 30 2022 | n/a | n/a | -AU$28m |
| Jun 30 2022 | AU$3m | AU$631k | -AU$30m |
Compensation vs Market: Riccardo's total compensation ($USD1.66M) is above average for companies of similar size in the Australian market ($USD291.23K).
Compensation vs Earnings: Riccardo's compensation has been consistent with company performance over the past year.
CEO
Riccardo Canevari
3.3yrs
Tenure
AU$2,652,983
Compensation
Mr. Riccardo Canevari is Managing Director & Chief Executive Officer at Radiopharm Theranostics Limited since September 13, 2021 and is its Director since 2021. He was Chief Commercial Officer of Advanced...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 3.8yrs | AU$478.85k | 6.8% A$ 3.5m | |
| MD, CEO & Director | 3.3yrs | AU$2.65m | 0.97% A$ 508.3k | |
| CFO, Joint Company Secretary & Director | 3.8yrs | AU$27.71k | 0.73% A$ 383.0k | |
| Chief Business Officer | 1.9yrs | AU$579.19k | 0.046% A$ 24.0k | |
| Chief Medical Officer | less than a year | no data | no data | |
| Joint Company Secretary | 3.2yrs | no data | no data |
3.2yrs
Average Tenure
68yo
Average Age
Experienced Management: RAD's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 3.8yrs | AU$478.85k | 6.8% A$ 3.5m | |
| MD, CEO & Director | 3.9yrs | AU$2.65m | 0.97% A$ 508.3k | |
| CFO, Joint Company Secretary & Director | less than a year | AU$27.71k | 0.73% A$ 383.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 3.8yrs | AU$476.52k | 0.23% A$ 118.9k | |
| Independent Non-Executive Director | 2.5yrs | AU$165.41k | 0.049% A$ 25.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 2.8yrs | AU$94.32k | 0.030% A$ 15.5k |
2.8yrs
Average Tenure
62yo
Average Age
Experienced Board: RAD's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 01:19 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Radiopharm Theranostics Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Hunter Diamond | Diamond Equity Research LLC |
| Justin Walsh | JonesTrading Institutional Services, LLC |